Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab, Cadonilimab, or Penpulimab + Chemo in Resectable HNSCC
NCT06444009Phase 2Recruiting
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab, cadonilimab, penpulimab in head and neck squamous cell carcinoma (HNSCC). Started Jul 2024; status: recruiting.
02
Drugs
ivonescimabcadonilimabpenpulimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06444009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06444009.